These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 28786273)

  • 21. Cardiovascular risk profiles in a hospital-based population of patients with psoriatic arthritis and ankylosing spondylitis: a cross-sectional study.
    Nissen CB; Hørslev-Petersen K; Primdahl J
    Rheumatol Int; 2017 Jan; 37(1):113-120. PubMed ID: 27889826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis.
    da Silva BS; Bonfá E; de Moraes JC; Saad CG; Ribeiro AC; Gonçalves CR; de Carvalho JF
    Biologicals; 2010 Sep; 38(5):567-9. PubMed ID: 20638299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors].
    Swierkot J; Madej M
    Pol Merkur Lekarski; 2011 Apr; 30(178):289-94. PubMed ID: 21595177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides.
    Braun J; Baraliakos X; Brandt J; Sieper J
    Scand J Rheumatol; 2005; 34(3):178-90. PubMed ID: 16134723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Voulgari PV
    Expert Rev Clin Immunol; 2010 Sep; 6(5):721-33. PubMed ID: 20828280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study.
    Smolen JS; Gladman D; McNeil HP; Mease PJ; Sieper J; Hojnik M; Nurwakagari P; Weinman J
    RMD Open; 2019; 5(1):e000585. PubMed ID: 30713716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.
    Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
    Rheumatol Int; 2019 Jan; 39(1):131-140. PubMed ID: 30415451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
    Szentpetery A; McKenna MJ; Murray BF; Ng CT; Brady JJ; Morrin M; Radovits B; Veale DJ; Fitzgerald O
    J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review.
    Gialouri CG; Pappa M; Evangelatos G; Nikiphorou E; Fragoulis GE
    Autoimmun Rev; 2023 Jul; 22(7):103357. PubMed ID: 37150489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology.
    Czókolyová M; Pusztai A; Végh E; Horváth Á; Szentpéteri A; Hamar A; Szamosi S; Hodosi K; Domján A; Szántó S; Kerekes G; Seres I; Harangi M; Paragh G; Szekanecz É; Szekanecz Z; Szűcs G
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission.
    Ramírez J; Inciarte-Mundo J; Cuervo A; Ruiz-Esquide V; Hernández MV; Sanmartí R; Cañete JD
    Clin Exp Rheumatol; 2017; 35(1):74-79. PubMed ID: 27749227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis.
    Zisman D; Haddad A; Hashoul S; Laor A; Bitterman H; Rosner I; Eder L; Balbir-Gurman A; Mader R; Milman U
    J Rheumatol; 2013 Jan; 40(1):16-22. PubMed ID: 23070992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
    Poddubnyy D; Rudwaleit M
    Expert Opin Drug Saf; 2011 Jul; 10(4):655-73. PubMed ID: 21554150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis.
    Deyab G; Hokstad I; Whist JE; Smastuen MC; Agewall S; Lyberg T; Ronda N; Mikkelsen K; Hjeltnes G; Hollan I
    Arthritis Res Ther; 2017 Oct; 19(1):232. PubMed ID: 29041979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
    Cantini F; Nannini C; Niccoli L
    Open Access Rheumatol; 2009; 1():163-178. PubMed ID: 27789989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of rheumatoid arthritis and spondylarthritis with biologics].
    Fiehn C
    Internist (Berl); 2022 Feb; 63(2):135-142. PubMed ID: 35029702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of biologic antirheumatic treatments on bone metabolism in rheumatoid arthritis and ankylosing spondylitis].
    Głuszko P
    Endokrynol Pol; 2009; 60(2):115-21. PubMed ID: 19396755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of anti-rheumatic treatment on selenium levels in inflammatory arthritis.
    Deyab G; Hokstad I; Aaseth J; Småstuen MC; Whist JE; Agewall S; Lyberg T; Tveiten D; Hjeltnes G; Zibara K; Hollan I
    J Trace Elem Med Biol; 2018 Sep; 49():91-97. PubMed ID: 29895378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disease-modifying antirheumatic drug therapy for psoriatic arthritis.
    Salvarani C; Cantini F; Olivieri I
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S71-5. PubMed ID: 12463452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register.
    Kay LJ; Griffiths ID;
    Rheumatology (Oxford); 2006 Nov; 45(11):1376-9. PubMed ID: 17040892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.